WLRN1d
New drug gives hope to South Floridians affected by Alzheimer’s
Called Donanemab, this treatment from Eli Lilly will be sold under its brand name, Kisunla, and works as an intravenous ...
A New Alzheimer’s Drug May Be the Most Effective One Yet
Eli Lilly's new drug, donanemab, targets amyloid proteins and slows cognitive decline more than others in its class.
Third FDA-approved Alzheimer’s drug can give patients more time with family
Alzheimer’s patients can temporarily lessen their symptoms with a recent FDA-approved drug that removes amyloid, or protein, ...
Las Vegas Sun13d
UNLV researcher optimistic as Alzheimer’s drug donanemab receives FDA approval
For Dr. Jeffrey Cummings, a brain health researcher and professor at UNLV, this is an exciting time in the fight against ...
FDA Approves Eli Lilly’s Alzheimer’s Drug Donanemab
Eli Lilly’s donanemab—to be sold under the brand name Kisunla—received regulatory approval as a monthly injection after an 18 ...
technologynetworks15d
New Alzheimer’s Drug Donanemab Approved by FDA
The drug donanemab (also known as Kisunla™) has been approved by the US Food and Drug Administration (FDA) for the treatment ...
The New York Times17d
New Drug Approved for Early Alzheimer’s
The drug, donanemab, to be sold under the brand name Kisunla, was shown in studies to modestly slow the pace of cognitive decline in early stages of the disease. It also had significant safety ...
Everyday Health10d
Donanemab and Lecanemab for Early Alzheimer’s: What You Need to Know
Donanemab (Kisunla) and lecanemab (Leqembi) slow early-stage Alzheimer’s progression by targeting beta-amyloid plaques in the ...
health.wusf.usf.edu1d
New drug gives hope to Floridians affected by Alzheimer’s disease
The FDA approved donanemab, which will be sold under the brand name Kisunla. The new drug helps slow decline in Alzheimer's patients with mild cognitive impairment.
CBS News16d
FDA approves new Alzheimer's treatment, donanemab from Eli Lilly
The Food and Drug Administration approved a new Alzheimer's treatment called donanemab on Tuesday, clearing the way for the third addition to a new class of drugs aimed at slowing the brain's ...
CNN17d
FDA approves donanemab, Eli Lilly’s treatment for early Alzheimer’s disease
The US Food and Drug Administration on Tuesday approved donanemab, a monoclonal antibody designed to slow the progression of early symptomatic Alzheimer’s disease. Donanemab, made by ...